Eric Palmer

Biography for Eric Palmer

Eric Palmer, Senior Editor

Eric Palmer is a business and technology journalist with more than three decades of prize-winning experience as a reporter and editor with daily, weekly, monthly and online publications. He was healthcare reporter for The Kansas City Star before becoming deputy business editor for the daily newspaper. He spent eight years as editor of The Kansas City Business Journal, which had a strong emphasis on the healthcare industry. On the personal side, he is an avid fly fisherman, cooks and collects wine, and likes to travel with his family. Eric is based in Kansas City and can be reached at epalmer@fiercemarkets.com.

Articles by Eric Palmer

Celgene's Abraxane wins another OK in Europe

Celgene's Abaxane is one of those cancer fighters that has proven effective against many forms of cancer, and so the company has sought approvals far and wide, sometimes successfully and other times not. Now it has been recommended in Europe to treat lung cancer.

Challenger says 2015 a year to send out your resume, pharma folks

Layoffs have been a common refrain for the pharma industry in recent years, but with the economy picking up, private equity flowing into the business and a bunch of great drugs coming online, layoffs were down last year and this year should be one in which hiring sucks up some of the displaced folks from years past. At least that is the contention of experts who track these matters closely.

Bristol-Myers says COO Caforio to take over as CEO

Chief Operating Officer Giovanni Caforio will take over the top exec job at Bristol-Myers Squibb on May 5, when 64-year-old Lamberto Andreotti steps down from the role he has held for 5 years and takes over instead as executive chairman of the board.

Janssen agrees to rebate cost of Olysio to England's NHS if it doesn't work

Johnson & Johnson's Janssen unit has agreed to offer England's National Health Service a money-back guarantee on its hep C fighter Olysio, even as the treatment won approval from the cost watchdog there.

AbbVie wins quick approval for its hep C treatment in Europe

AbbVie has won European Commission approval for its oral hepatitis C cocktail, offering some positive news after some disappointments for the U.S. drugmaker in recent months. It also sets the stage for the drugmaker to take its marketing battle with Gilead Sciences to another continent.

Sanofi turns to Boehringer Ingelheim to beef up its biologics production

Sanofi and Regeneron are hard at work on a number of promising monoclonal antibodies, but Sanofi needs more manufacturing capacity to produce them. Instead of building its own like some of its peers, the French company has struck a deal to tap into a Boehringer Ingelheim plant in Germany.

Daiichi Sankyo to pay $39M to settle DOJ claims it paid kickbacks to docs

Japanese drugmaker Daiichi Sankyo will pay the $39 million to the state and federal health programs, and a whislteblower, to settle claims it paid doctors kickbacks to prescribe some of its drugs, Reuters reports.

Bristol-Myers gets U.K. boost for blockbuster contender Opdivo, weeks after FDA approval

Bristol-Myers Squibb just snagged U.S. approval for its new PD-1 cancer immunotherapy Opdivo, but already is building some momentum for the drug it expects to lead its growth this year. Just two weeks after the FDA gave the melanoma drug an early approval, the U.K.s Medicines and Healthcare products Regulatory Agency (MHRA), has tagged it with designation that could lead to early approval there.

FDA draws line in sand over its orphan drug policies

The FDA says it will abide by a court ruling stating it has to grant orphan drug exclusivity to Depomed's Gralise. But the agency has drawn a line in the sand, saying it does not intend to extend the same benefit to any other drugmakers under the same circumstances.

Drug groups ask Supreme Court to pull constitutionality out from under California drug disposal law

Having been unable to persuade a federal court or an appeals court that a California county's mandate that drugmakers pay for the disposal of unused meds was off base, PhRMA, BIO and GPhA are going to the ultimate arbiter of legal matters, the U.S. Supreme Court.